HEADER TRANSFERASE 09-AUG-00 1FK9 TITLE CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP- TITLE 2 266(EFAVIRENZ) COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 RT, A-CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66; COMPND 5 EC: 2.7.7.49; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: COMPLEXED WITH DMP-266(EFAVIRENZ); COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: HIV-1 RT, B-CHAIN; COMPND 10 CHAIN: B; COMPND 11 FRAGMENT: P51; COMPND 12 EC: 2.7.7.49; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 STRAIN: HXB2 ISOLATE; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 9 ORGANISM_TAXID: 11676; SOURCE 10 STRAIN: HXB2 ISOLATE; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HIV-1 REVERSE TRANSCRIPTASE, AIDS, NON-NUCLEOSIDE INHIBITOR, DMP-266, KEYWDS 2 EFAVIRENZ, DRUG DESIGN, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART,D.K.STAMMERS REVDAT 6 01-FEB-17 1FK9 1 AUTHOR REVDAT 5 18-JUL-12 1FK9 1 HETSYN VERSN REVDAT 4 24-FEB-09 1FK9 1 VERSN REVDAT 3 06-JAN-04 1FK9 3 SOURCE JRNL REMARK MODRES REVDAT 3 2 3 HETATM MASTER REVDAT 2 28-FEB-01 1FK9 1 ATOM REMARK REVDAT 1 03-NOV-00 1FK9 0 JRNL AUTH J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART,D.K.STAMMERS JRNL TITL STRUCTURAL BASIS FOR THE RESILIENCE OF EFAVIRENZ (DMP-266) JRNL TITL 2 TO DRUG RESISTANCE MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE. JRNL REF STRUCTURE FOLD.DES. V. 8 1089 2000 JRNL REFN ISSN 0969-2126 JRNL PMID 11080630 JRNL DOI 10.1016/S0969-2126(00)00513-X REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.REN,C.NICHOLS,L.E.BIRD,T.FUJIWARA,H.SUGINOTO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL BINDING OF THE SECOND GENERATTION NON-NUCLEOSIDE INHIBITOR REMARK 1 TITL 2 S-1153 TO HIV-1 REVERSE TRANSCRIPTASE INVOLVES EXTENSIVE REMARK 1 TITL 3 MAIN CHAIN HYDROGEN BONDING REMARK 1 REF J.BIOL.CHEM. V. 275 14316 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.19.14316 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD,S.IKEMIZU, REMARK 1 AUTH 2 M.SLATER,J.MILTON,J.BALZARINI,D.I.STUART,D.K.STAMMERS REMARK 1 TITL PHENETHYLTHIAZOLYLTHIOUREA (PETT) NON-NUCLEOSIDE INHIBITORS REMARK 1 TITL 2 OF HIV-1 AND HIV-2 REVERSE TRANSCRIPTASES: STRUCTURAL AND REMARK 1 TITL 3 BIOCHEMICAL ANALYSES REMARK 1 REF J.BIOL.CHEM. V. 275 5633 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.8.5633 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF THE BINDING MODES OF REMARK 1 TITL 2 NON-NUCLEOSIDE THIAZOLOISOINDOLINONE INHIBITORS TO HIV-1 REMARK 1 TITL 3 REVERSE TRANSCRIPTASE AND COMPARISON WITH MODELING STUDIES REMARK 1 REF J.MED.CHEM. V. 42 3845 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990275T REMARK 1 REFERENCE 4 REMARK 1 AUTH A.L.HOPKINS,J.REN,H.TANAKA,M.BABA,M.OKAMATO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL DESIGN OF MKC-442 (EMIVIRINE) ANALOGUES WITH IMPROVED REMARK 1 TITL 2 ACTIVITY AGAINST DRUG-RESISTANT HIV MUTANTS REMARK 1 REF J.MED.CHEM. V. 42 4500 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990192C REMARK 1 REFERENCE 5 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,J.WARREN,J.BALZARINI, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF REVERSE TRANSCRIPTASE IN COMPLEX WITH REMARK 1 TITL 2 CARBOXANILIDE DERIVATIVES REMARK 1 REF BIOCHEMISTRY V. 37 14394 1998 REMARK 1 REFN ISSN 0006-2960 REMARK 1 DOI 10.1021/BI981309M REMARK 1 REFERENCE 6 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,E.Y.JONES,I.KIRBY,J.KEELING, REMARK 1 AUTH 2 C.K.ROSS,B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL 3'-AZIDO-3'-DEOXYTHYMIDINE DRUG RESISTANCE MUTATIONS IN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CAN INDUCE LONG RANGE REMARK 1 TITL 3 CONFORMATIONAL CHANGES REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 9518 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.95.16.9518 REMARK 1 REFERENCE 7 REMARK 1 AUTH R.M.ESNOUF,J.REN,E.GARMAN,D.O.SOMERS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL CONTINUOUS AND DISCONTINUOUS CHANGES IN THE UNIT CELL OF REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CRYSTALS ON DEHYDRATION REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 54 938 1998 REMARK 1 REFN ISSN 0907-4449 REMARK 1 DOI 10.1107/S0907444998004284 REMARK 1 REFERENCE 8 REMARK 1 AUTH R.M.ESNOUF,J.REN,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL UNIQUE FEATURES IN THE STRUCTURE OF THE COMPLEX BETWEEN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 BIS(HETEROARYL)PIPERAZINE (BHAP) U-90152 EXPLAIN RESISTANCE REMARK 1 TITL 4 MUTATIONS FOR THIS NON-NUCLEOSIDE INHIBITOR REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 94 3984 1997 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.94.8.3984 REMARK 1 REFERENCE 9 REMARK 1 AUTH A.L HOPKINS,J.REN,R.M.ESNOUF,B.E.WILLCOX,E.Y.JONES,C.K.ROSS, REMARK 1 AUTH 2 T.MIYASAKA,R.T.WALKER,H.TANAKA,D.K.STAMMERS,D.I.STUART REMARK 1 TITL COMPLEXES OF HIV-1 REVERSE TRANSCRIPTASE WITH INHIBITORS OF REMARK 1 TITL 2 THE HEPT SERIES REVEAL CONFORMATIONAL CHANGES RELEVANT TO REMARK 1 TITL 3 THE DESIGN OF POTENT NON-NUCLEOSIDE INHIBITORS REMARK 1 REF J.MED.CHEM. V. 39 1589 1996 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM960056X REMARK 1 REFERENCE 10 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K STAMMERS,D.I.STUART REMARK 1 TITL THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH REMARK 1 TITL 2 9-CHLORO-TIBO: LESSONS FOR INHIBITOR DESIGN REMARK 1 REF STRUCTURE V. 3 915 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 11 REMARK 1 AUTH J.REN,R.M.ESNOUF,E.GARMAN,D.O.SOMERS,C.K.ROSS,I.KIRBY, REMARK 1 AUTH 2 J.KEELING,G.DARBY,E.Y.JONES,D.I.STUART,D.K.STAMMERS REMARK 1 TITL HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR REMARK 1 TITL 2 RT-INHIBITOR COMPLEXES REMARK 1 REF NAT.STRUCT.BIOL. V. 2 293 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 12 REMARK 1 AUTH R.M.ESNOUF,J.REN,C.K.ROSS,E.Y.JONES,D.K.STAMMERS,D.I.STUART REMARK 1 TITL MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY REMARK 1 TITL 2 NON-NUCLEOSIDE INHIBITORS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 303 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 13 REMARK 1 AUTH D.K.STAMMERS,D.O.SOMERS,C.K.ROSS,I.KIRBY,P.H.RAY,J.E.WILSON, REMARK 1 AUTH 2 M.NORMAN,J.REN,R.M.ESNOUF,E.GARMAN,E.Y.JONES,D.I.STUART REMARK 1 TITL CRYSTALS OF HIV-1 REVERSE TRANSCRIPTASE DIFFRACTING TO 2.2 REMARK 1 TITL 2 ANGSTROM RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 242 586 1994 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1994.1604 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.0 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 85.2 REMARK 3 NUMBER OF REFLECTIONS : 31707 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.218 REMARK 3 FREE R VALUE : 0.301 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1541 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7606 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 21 REMARK 3 SOLVENT ATOMS : 113 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 62.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1FK9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 16-AUG-00. REMARK 100 THE RCSB ID CODE IS RCSB011666. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-AUG-97 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX7.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.488 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 31707 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -1.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 85.2 REMARK 200 DATA REDUNDANCY : 2.750 REMARK 200 R MERGE (I) : 0.06200 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.59 REMARK 200 COMPLETENESS FOR SHELL (%) : 69.7 REMARK 200 DATA REDUNDANCY IN SHELL : 2.20 REMARK 200 R MERGE FOR SHELL (I) : 0.36300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.54 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SEE REFERENCE 13, PH 5, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 69.90000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 32.70000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.50000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 32.70000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 69.90000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.50000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: HIV-1 RT IS A HETERODIMER CONSISTING OF A P66 AND A P51 REMARK 300 SUBUNITS, THE P51 CONTAINS THE FIRST 440 RESIDUES OF THE P66. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5420 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 44140 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PRO A 1 REMARK 465 ILE A 2 REMARK 465 SER A 3 REMARK 465 LYS A 64 REMARK 465 LYS A 65 REMARK 465 LYS A 66 REMARK 465 ASP A 67 REMARK 465 SER A 68 REMARK 465 GLY A 444 REMARK 465 ALA A 445 REMARK 465 ALA A 446 REMARK 465 ASN A 447 REMARK 465 ARG A 448 REMARK 465 GLU A 449 REMARK 465 THR A 450 REMARK 465 LYS A 451 REMARK 465 LEU A 452 REMARK 465 GLY A 453 REMARK 465 LYS A 454 REMARK 465 LYS A 540 REMARK 465 GLY A 541 REMARK 465 ILE A 542 REMARK 465 GLY A 543 REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 SER B 3 REMARK 465 PRO B 4 REMARK 465 ILE B 5 REMARK 465 GLU B 89 REMARK 465 VAL B 90 REMARK 465 GLN B 91 REMARK 465 LEU B 92 REMARK 465 GLY B 93 REMARK 465 HIS B 221 REMARK 465 GLN B 222 REMARK 465 LYS B 223 REMARK 465 GLU B 224 REMARK 465 PRO B 225 REMARK 465 PRO B 226 REMARK 465 PHE B 227 REMARK 465 LEU B 228 REMARK 465 TRP B 229 REMARK 465 MET B 230 REMARK 465 MET B 357 REMARK 465 ARG B 358 REMARK 465 GLY B 359 REMARK 465 ALA B 360 REMARK 465 HIS B 361 REMARK 465 LEU B 429 REMARK 465 GLU B 430 REMARK 465 LYS B 431 REMARK 465 GLU B 432 REMARK 465 PRO B 433 REMARK 465 ILE B 434 REMARK 465 VAL B 435 REMARK 465 GLY B 436 REMARK 465 ALA B 437 REMARK 465 GLU B 438 REMARK 465 THR B 439 REMARK 465 PHE B 440 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 52 24.57 -68.88 REMARK 500 GLN A 85 160.05 -47.84 REMARK 500 GLN A 91 91.40 24.42 REMARK 500 LEU A 92 -84.95 -55.31 REMARK 500 ALA A 114 -78.29 -46.88 REMARK 500 PHE A 116 32.12 -86.68 REMARK 500 ASP A 121 107.27 -43.24 REMARK 500 ASP A 123 -11.45 -45.58 REMARK 500 VAL A 148 -164.87 -118.79 REMARK 500 PHE A 171 -39.29 -38.50 REMARK 500 MET A 184 -128.05 51.56 REMARK 500 ILE A 195 -45.02 -27.58 REMARK 500 LYS A 219 -44.20 -21.98 REMARK 500 HIS A 221 35.49 -98.31 REMARK 500 ILE A 270 -44.25 -139.92 REMARK 500 ALA A 288 137.76 -179.86 REMARK 500 PRO A 345 109.27 -28.27 REMARK 500 PHE A 346 -8.94 74.98 REMARK 500 PRO A 392 42.53 -80.71 REMARK 500 TRP A 402 -84.11 -42.35 REMARK 500 GLU A 413 123.55 -34.43 REMARK 500 LYS A 465 107.70 -162.95 REMARK 500 ASP A 471 84.59 62.00 REMARK 500 TYR A 501 -76.72 -59.35 REMARK 500 PHE B 87 77.38 -113.07 REMARK 500 PHE B 116 -10.37 -49.60 REMARK 500 SER B 162 -80.38 -44.14 REMARK 500 PRO B 176 8.39 -64.18 REMARK 500 MET B 184 -134.65 59.84 REMARK 500 SER B 191 -174.47 -175.95 REMARK 500 THR B 200 -72.62 -78.76 REMARK 500 ARG B 211 46.84 -84.39 REMARK 500 TRP B 212 -18.49 -171.27 REMARK 500 THR B 216 102.78 25.64 REMARK 500 LYS B 219 -139.75 -152.87 REMARK 500 LEU B 283 70.79 -116.47 REMARK 500 PHE B 346 -0.97 69.97 REMARK 500 LYS B 347 68.77 -113.78 REMARK 500 PRO B 421 22.91 -63.95 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A1040 DISTANCE = 5.87 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EFZ A 999 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1RTV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1RTH RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1VRU RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH ALPHA-APA REMARK 900 RELATED ID: 1RTI RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH HEPT REMARK 900 RELATED ID: 1RTJ RELATED DB: PDB REMARK 900 HIV-1 RT REMARK 900 RELATED ID: 1REV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 9-CL-TIBO REMARK 900 RELATED ID: 1RT1 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH MKC-442 REMARK 900 RELATED ID: 1RT2 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-651 REMARK 900 RELATED ID: 1KLM RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BHAP (U-90152) REMARK 900 RELATED ID: 1RT3 RELATED DB: PDB REMARK 900 AZT DRUG RESISTANT HIV-1 RT MUTANT (RTMC) COMPLEXED WITH REMARK 900 1051U91 REMARK 900 RELATED ID: 1RT4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1RT5 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-10 REMARK 900 RELATED ID: 1RT6 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-38 REMARK 900 RELATED ID: 1RT7 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-84 REMARK 900 RELATED ID: 1C0T RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+21.1326 REMARK 900 RELATED ID: 1C0U RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+50.0934 REMARK 900 RELATED ID: 1C1B RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH GCA-186 REMARK 900 RELATED ID: 1C1C RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-6123 REMARK 900 RELATED ID: 1DTQ RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-1 REMARK 900 RELATED ID: 1DTT RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-2 REMARK 900 RELATED ID: 1EP4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH S-1153 DBREF 1FK9 A 1 543 UNP P04585 POL_HV1H2 587 1129 DBREF 1FK9 B 1 440 UNP P04585 POL_HV1H2 587 1026 SEQRES 1 A 543 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 543 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 543 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 543 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 543 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 543 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 543 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 543 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 A 543 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 543 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 543 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 543 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 543 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 543 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 543 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 543 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 543 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 543 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 543 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 543 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 543 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 543 ILE LYS VAL ARG GLN LEU CSD LYS LEU LEU ARG GLY THR SEQRES 23 A 543 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 543 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 543 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 543 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 543 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 543 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 543 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 543 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 543 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 543 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 543 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 543 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 543 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 543 GLY TYR VAL THR ASN ARG GLY ARG GLN LYS VAL VAL THR SEQRES 37 A 543 LEU THR ASP THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 543 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 543 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 543 ALA GLN PRO ASP GLN SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 543 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 543 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY SEQRES 1 B 440 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 440 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 440 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 440 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 440 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 440 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 440 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 440 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 B 440 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 440 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 440 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 440 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 440 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 440 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 440 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 440 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 440 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 440 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 440 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 440 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 440 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 440 ILE LYS VAL ARG GLN LEU CYS LYS LEU LEU ARG GLY THR SEQRES 23 B 440 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 440 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 440 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 440 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 440 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 440 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 440 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 440 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 440 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 440 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 440 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 440 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE MODRES 1FK9 CSD A 280 CYS 3-SULFINOALANINE HET CSD A 280 8 HET EFZ A 999 21 HETNAM CSD 3-SULFINOALANINE HETNAM EFZ (-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1, HETNAM 2 EFZ 4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE HETSYN EFZ DMP-266; EFAVIRENZ FORMUL 1 CSD C3 H7 N O4 S FORMUL 3 EFZ C14 H9 CL F3 N O2 FORMUL 4 HOH *113(H2 O) HELIX 1 1 THR A 27 GLU A 44 1 18 HELIX 2 2 PHE A 77 THR A 84 1 8 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 ALA A 114 VAL A 118 5 5 HELIX 5 5 ASP A 121 LYS A 126 1 6 HELIX 6 6 TYR A 127 ALA A 129 5 3 HELIX 7 7 GLY A 155 GLN A 174 1 20 HELIX 8 8 GLU A 194 ARG A 211 1 18 HELIX 9 9 ASP A 218 GLN A 222 5 5 HELIX 10 10 THR A 253 GLN A 269 1 17 HELIX 11 11 THR A 296 GLU A 312 1 17 HELIX 12 12 ASN A 363 GLY A 384 1 22 HELIX 13 13 GLN A 394 TYR A 405 1 12 HELIX 14 14 THR A 473 SER A 489 1 17 HELIX 15 15 SER A 499 ALA A 508 1 10 HELIX 16 16 SER A 515 LYS A 528 1 14 HELIX 17 17 THR B 27 GLU B 44 1 18 HELIX 18 18 PHE B 77 THR B 84 1 8 HELIX 19 19 GLY B 99 LYS B 103 5 5 HELIX 20 20 GLY B 112 TYR B 115 5 4 HELIX 21 21 ASP B 121 LYS B 126 1 6 HELIX 22 22 TYR B 127 ALA B 129 5 3 HELIX 23 23 SER B 134 GLU B 138 5 5 HELIX 24 24 LYS B 154 PHE B 160 1 7 HELIX 25 25 PHE B 160 ASN B 175 1 16 HELIX 26 26 GLU B 194 ARG B 211 1 18 HELIX 27 27 HIS B 235 TRP B 239 5 5 HELIX 28 28 THR B 253 SER B 268 1 16 HELIX 29 29 VAL B 276 LEU B 282 1 7 HELIX 30 30 THR B 296 LYS B 311 1 16 HELIX 31 31 ASN B 363 GLY B 384 1 22 HELIX 32 32 GLN B 394 TRP B 402 1 9 HELIX 33 33 THR B 403 TYR B 405 5 3 HELIX 34 34 LEU B 422 TYR B 427 5 6 SHEET 1 A 3 ILE A 47 ILE A 50 0 SHEET 2 A 3 ILE A 142 TYR A 146 -1 O ARG A 143 N ILE A 50 SHEET 3 A 3 PHE A 130 ILE A 132 -1 O PHE A 130 N TYR A 144 SHEET 1 B 2 VAL A 60 ILE A 63 0 SHEET 2 B 2 ARG A 72 VAL A 75 -1 O ARG A 72 N ILE A 63 SHEET 1 C 3 SER A 105 ASP A 110 0 SHEET 2 C 3 ASP A 186 SER A 191 -1 O LEU A 187 N LEU A 109 SHEET 3 C 3 VAL A 179 TYR A 183 -1 O VAL A 179 N GLY A 190 SHEET 1 D 2 PHE A 227 TRP A 229 0 SHEET 2 D 2 TYR A 232 LEU A 234 -1 O TYR A 232 N TRP A 229 SHEET 1 E 5 LYS A 347 TYR A 354 0 SHEET 2 E 5 TRP A 337 GLU A 344 -1 N TRP A 337 O TYR A 354 SHEET 3 E 5 ILE A 326 LYS A 331 -1 N ILE A 326 O TYR A 342 SHEET 4 E 5 LYS A 388 LEU A 391 1 O LYS A 388 N ALA A 327 SHEET 5 E 5 TRP A 414 PHE A 416 1 N GLU A 415 O PHE A 389 SHEET 1 F 2 HIS A 361 THR A 362 0 SHEET 2 F 2 GLN A 512 SER A 513 -1 N GLN A 512 O THR A 362 SHEET 1 G 5 GLN A 464 VAL A 466 0 SHEET 2 G 5 GLY A 456 THR A 459 -1 O TYR A 457 N LYS A 465 SHEET 3 G 5 THR A 439 VAL A 442 -1 N TYR A 441 O VAL A 458 SHEET 4 G 5 GLU A 492 THR A 497 1 O ASN A 494 N PHE A 440 SHEET 5 G 5 LYS A 530 TRP A 535 1 O LYS A 530 N VAL A 493 SHEET 1 H 3 ILE B 47 LYS B 49 0 SHEET 2 H 3 ILE B 142 TYR B 146 -1 O GLN B 145 N SER B 48 SHEET 3 H 3 PHE B 130 ILE B 132 -1 N PHE B 130 O TYR B 144 SHEET 1 I 2 VAL B 60 LYS B 64 0 SHEET 2 I 2 TRP B 71 VAL B 75 -1 N ARG B 72 O ILE B 63 SHEET 1 J 3 SER B 105 ASP B 110 0 SHEET 2 J 3 ASP B 186 SER B 191 -1 O LEU B 187 N LEU B 109 SHEET 3 J 3 VAL B 179 TYR B 183 -1 O VAL B 179 N GLY B 190 SHEET 1 K 5 LYS B 347 ALA B 355 0 SHEET 2 K 5 GLN B 336 GLU B 344 -1 N TRP B 337 O TYR B 354 SHEET 3 K 5 ILE B 326 LYS B 331 -1 N ILE B 326 O TYR B 342 SHEET 4 K 5 LYS B 388 LEU B 391 1 O LYS B 388 N ALA B 327 SHEET 5 K 5 GLU B 413 PHE B 416 1 O GLU B 413 N PHE B 389 LINK C LEU A 279 N CSD A 280 1555 1555 1.33 LINK C CSD A 280 N LYS A 281 1555 1555 1.33 CISPEP 1 PRO A 225 PRO A 226 0 -0.28 CISPEP 2 PRO A 420 PRO A 421 0 -0.25 SITE 1 AC1 9 LEU A 100 LYS A 101 LYS A 103 VAL A 179 SITE 2 AC1 9 TYR A 181 TYR A 188 GLY A 190 HIS A 235 SITE 3 AC1 9 PRO A 236 CRYST1 139.800 115.000 65.400 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007153 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008696 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015291 0.00000